Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 2/20 | 0.52 |
| ▸ | XDH | P47989 | 5/20 | 0.47 |
| ▸ | DHFR | P00374 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | HPRT1 | P00492 | 5/20 | 0.43 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.43 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12820649 | 0.82 | PNP (0.57) | PNPXDHDHFRALDH1A1MAPT | |
| SCHEMBL12958955 | 0.81 | XDH (0.49) | PNPXDHDHFRALDH1A1MAPT | |
| SCHEMBL12820588 | 0.80 | PNP (0.60) | PNPADORA2AADORA2BADORA1HPRT1 | |
| SCHEMBL12968301 | 0.79 | PNP (0.48) | PNPXDHDHFRALDH1A1MAPT | |
| SCHEMBL2982028 | 0.79 | XDH (0.50) | PNPXDHDHFRALDH1A1MAPT | |
| SCHEMBL1765838 | 0.79 | PNP (0.48) | PNPXDHDHFRALDH1A1MAPT | |
| SCHEMBL18520114 | 0.79 | PNP (0.48) | PNPXDHDHFRALDH1A1HPRT1 | |
| SCHEMBL13587333 | 0.79 | PNP (0.48) | PNPXDHDHFRALDH1A1MAPT | |
| SCHEMBL13046994 | 0.78 | ALDH1A1 (0.53) | PNPXDHDHFRALDH1A1MAPT | |
| SCHEMBL16755642 | 0.77 | PNP (0.46) | PNPXDHDHFRALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0775142-A1 | SUBSTITUTED O6 -BENZYLGUANINES AND 6(4)-BENZYLOXYPYRIMIDINES | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1997-05-28 | — | — | EP | claimed |
| US-20120252791-A1 | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain | CHILDREN'S MEDICAL CENTER CORPORATION | 2012-10-04 | — | — | US | disclosed |
| US-20120252791-A1 | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain | CHILDREN'S MEDICAL CENTER CORPORATION | 2012-10-04 | — | — | US | disclosed |
| WO-2011035009-A1 | HETEROCYCLIC GTP CYCLOHYDROLASE 1 INHIBITORS FOR THE TREATMENT OF PAIN | HERCULES TECHNOLOGY MANAGEMENT CO V, INC. (US) | 2011-03-24 | — | — | WO | disclosed |
| US-20090299049-A1 | Bicyclic Compounds and Their Use | REPLIZYME LIMITED (GB) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252791-A1 | Heterocyclic GTP Cyclohydrolase 1 Inhibitors For the Treatment of Pain | GGH, GGPS1, GGT1 | PNP 189/4885XDH 1422/4885DHFR 66/4885 |
| US-20090299049-A1 | Bicyclic Compounds and Their Use | ERCC4, PARP1, ERCC5 | PNP 73/4885XDH 1858/4885DHFR 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.